Scarica l'app Stockscreener
4.27
4.15%
0.17
Dopo l'orario di chiusura:
4.20
-0.07
-1.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AVXL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.10
Aprire:
$4.09
Volume 24 ore:
1.27M
Relative Volume:
0.49
Capitalizzazione di mercato:
$381.52M
Reddito:
-
Utile/perdita netta:
$-48.17M
Rapporto P/E:
-7.4912
EPS:
-0.57
Flusso di cassa netto:
$-37.10M
1 W Prestazione:
+19.94%
1M Prestazione:
-1.61%
6M Prestazione:
-58.10%
1 anno Prestazione:
-62.64%
Intervallo 1D:
$3.97
$4.31
Intervallo di 1 settimana:
$3.495
$4.37
Portata 52W:
$2.86
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Nome
Anavex Life Sciences Corporation
Settore
Industria
Telefono
844-689-3939
Indirizzo
630 5TH AVENUE, NEW YORK
Confronta AVXL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
4.27 | 366.33M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-09-23 | Iniziato | BTIG Research | Buy |
| 2020-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-28 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-02-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-18 | Iniziato | Janney | Buy |
| 2018-05-16 | Ripresa | Maxim Group | Buy |
| 2018-03-08 | Iniziato | ROTH Capital | Buy |
| 2018-02-13 | Reiterato | Maxim Group | Buy |
| 2017-09-29 | Ripresa | Noble Financial | Buy |
| 2017-02-07 | Iniziato | Noble Financial | Buy |
| 2016-03-29 | Iniziato | FBR Capital | Outperform |
Mostra tutto
Anavex Life Sciences Corporation Borsa (AVXL) Ultime notizie
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm - PR Newswire
Will Anavex Life Sciences Corp. stock continue upward momentum2025 Stock Rankings & Daily Stock Trend Watchlist - ulpravda.ru
Is Anavex Life Sciences Corp. stock a buy for dividend growth2025 Major Catalysts & Free Real-Time Volume Trigger Notifications - ulpravda.ru
Anavex Life Sciences Appoints Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology - Quiver Quantitative
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology - Anavex Life Sciences
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Shares Surge on Encouraging Regulatory Development - AD HOC NEWS
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program - Anavex Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL - FinancialContent
Anavex Life Sciences (AVXL) Receives Reaffirmed Buy Rating from D. Boral Capital | AVXL Stock News - GuruFocus
D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. Invited by FDA to Present Alzheimer’s Disease Clinical Trial Results - Quiver Quantitative
FDA takes closer look at experimental Alzheimer’s pill in key meeting - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Prime Publishers, Inc.
Analyzing 3 Promising Penny Stocks With Market Caps Over $60M - simplywall.st
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - GlobeNewswire
What analysts say about Anavex Life Sciences Corp stockHigh Beta Stocks & Maximize ROI With Proven Growth Stocks - earlytimes.in
Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright - MarketBeat
Can Anavex Life Sciences Corp. stock sustain free cash flow growth2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Can Anavex Life Sciences Corp. stock resist market sell offs2025 Valuation Update & Weekly Watchlist for Consistent Profits - DonanımHaber
Rate Cut: Why Anavex Life Sciences Corp stock could be next big winner2025 Trading Volume Trends & Accurate Buy Signal Notifications - moha.gov.vn
AVXL Maintains Buy Rating with Price Target Unchanged at $24 by D. Boral Capital | AVXL Stock News - GuruFocus
Why Anavex Life Sciences Corp. stock could rally in 2025Stock Surge & Risk Controlled Swing Trade Alerts - ulpravda.ru
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's. Read more here. - Seeking Alpha
Anavex Life Sciences Requests European Medicines Agency to Re-evaluate Blarcamesine as Early Alzheimer's Treatment - marketscreener.com
What catalysts could drive Anavex Life Sciences Corp. stock higher2025 Institutional Moves & Technical Pattern Recognition Alerts - Улправда
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion - The Manila Times
Anavex Life Sciences requests EMA to re-examine blarcamesine for Alzheimer's - marketscreener.com
EU regulators asked to revisit an experimental pill for early Alzheimer’s - Stock Titan
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Anavex Life Sciences (AVXL): Analyst Ratings Update for December 15, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from D. Boral Capital - MarketBeat
Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday - Defense World
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences Updates on Regulatory Review for Blarcamesine in Treating Early Alzheimer's Disease - Quiver Quantitative
Anavex (NASDAQ: AVXL) to seek CHMP re-exam after EU negative view on blarcamesine - Stock Titan
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025) - ts2.tech
Anavex (AVXL) Faces EMA Setback on Alzheimer's Drug Application - GuruFocus
Anavex Life Sciences Corporation Azioni (AVXL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):